Biological function of UCA1 in hepatocellular carcinoma and its clinical significance: Investigation with in vitro and meta-analysis
Introduction
Hepatocellular carcinoma (HCC), one subtype of liver cancer originating from hepatic cells, has the highest incidence of any cancer in the world. HCC is also the second main cause of cancer-related death in males and the sixth main cause in females worldwide. HCC mainly occurs in Southeast Asia and East Asia, especially in China, as well as in northern and western Africa [1,2]. The pathogenesis of HCC involves several factors, including hepatitis B virus (HBV) chronic infection, hepatitis C virus (HCV) infection, unrestrained consumption of alcohol, non-alcoholic fatty liver disease, diabetes and dietary exposure to aflatoxin [[3], [4], [5]]. Presently, even though the 5-year survival rate of HCC patients has been improved via resection in the early stage and liver transplantation, metastasis and recurrence remain the main reason for treatment failure [[6], [7], [8], [9]]. Furthermore, when patients are diagnosed with HCC, most are at intermediate or advanced stages; this is yet another reason for poor prognosis of HCC [[10], [11], [12]]. Hence, determining the molecular mechanisms underlying the early pathogenesis of HCC is urgently needed.
Urothelial cancer associated 1 (UCA1, Gene ID: 652995), also known as CUDR (cancer upregulated drug resistant) noncoding RNA, is a long noncoding RNA (lncRNA) that has been reported to be universally upregulated in many malignancies [[13], [14], [15], [16], [17]]. Moreover, UCA1 can act as an unfavourable biomarker for predicting malignant phenotypes and prognosis [[18], [19], [20]]. In breast cancer, UCA1 could boost the tamoxifen resistance of tumour cells [21]. This suggests that UCA1 may also play a specific role in the treatment of different malignancies.
There is some evidence to suggest that UCA1 is notably upregulated in HCC serum and may be applied as a non-invasive marker for HCC screening and prognostic prediction [[22], [23], [24]]. Additionally, UCA1 has been upregulated in HCC tissues and cell lines, and the expression of UCA1 is associated with several clinical features and malignant behaviours in HCC [[23], [24], [25], [26], [27], [28], [29]]. However, none of these findings have completely interpreted the role of UCA1 in HCC, and the sample size used in each study was small. Thus, we conducted this investigation to validate the expression of UCA1 and its relationship with TNM stage in 41 HCC tissues and their paired noncancerous adjacent tissues by real-time qPCR. Furthermore, we also explored the biological functions of UCA1 in vitro with HCC cell lines. Most importantly, we conducted a comprehensive meta-analysis and bioinformatics investigation based on peer-reviewed literature and in silico approaches to further summarise the clinical value and functions of UCA1 in HCC.
Section snippets
Quantitative real-time RT-PCR assay
In total, 41 HCC cases were gathered from First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, China) from December 2016 to December 2017. The tissues were collected randomly from patients who were undergoing surgical resection without treatment. The informed consent to use the samples in research was provided by the patients or their families. Formal ethical approvement was given by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University to
UCA1 expression was remarkably upregulated in HCC tissues by in-house qRT-PCR
The transcription level of UCA1 was more significantly upregulated in HCC tissues than in adjacent noncancerous tissues (P = 0.0006, Fig. 1A) based on qRT-PCR. We also observed that the expression of UCA1 was associated with TNM stage. UCA1 expression was profoundly higher in advanced stages of III and IV than in early stages of I and II (Fig. 1B). Furthermore, the AUC of UCA1 was 0.734 (95% CI, 0.626–0.841, P = 0.0003, Fig. 1C).
Function of UCA1 siRNA on malignant phenotypes of HCC cells
The siRNA transfection efficiency was more than 90%, and UCA1
Discussion
The stubbornly high morbidity and mortality of HCC warrants a deeper understanding of the biological process underlying this situation. Several recent studies have reported that lncRNA is becoming increasingly popular for monitoring the clinical outcomes and targeted therapy of HCC patients due to its diverse functions [[43], [44], [45]]. Here, our findings illuminated the significantly upregulated lncRNA UCA1 in HCC tissues. Reducing the expression levels of UCA1 suppressed the proliferation
Conclusion
Taken together, our results underscore that the lncRNA UCA1 siRNAs were notable in inhibiting proliferation and inducing apoptosis of HCC cells. Significant clinical values consistent with its functional phenotype indicate the significant potential of UCA1 in the screening, prognosis and treatment evaluation of HCC.
Disclosure of conflict of interest
The authors declare no competing financial interests.
Acknowledgment
The study was supported by Innovation Project of Guangxi Graduate Education (YCBZ2017040).
References (52)
- et al.
Long noncoding RNA UCA1 promotes tumour metastasis by inducing GRK2 degradation in gastric cancer
Cancer Lett.
(2017) - et al.
Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma
Transl. Res.
(2016) - et al.
Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study
Cancer Cell Int.
(2016) - et al.
Down-regulation of miR-26a-5p in hepatocellular carcinoma: a qRT-PCR and bioinformatics study
Pathol. Res. Pract.
(2017) - et al.
Long non-coding RNAs as biomarkers and therapeutic targets: recent insights into hepatocellular carcinoma
Life Sci.
(2017) - et al.
Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets
J. Hepatol.
(2017) - et al.
LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p
Cancer Lett.
(2016) - et al.
Hallmarks of cancer: the next generation
Cell
(2011) - et al.
The Hippo pathway in hepatocellular carcinoma: non-coding RNAs in action
Cancer Lett.
(2017) - et al.
Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening
Liver Int.
(2018)
Diagnostic value of strand-specific miRNA-101-3p and miRNA-101-5p for hepatocellular carcinoma and a bioinformatic analysis of their possible mechanism of action
FEBS Open Bio
The impact of treatment of hepatitis C with DAAs on the occurrence of HCC
Liver Int.
T cell-associated immunotherapy for hepatocellular carcinoma
Cell. Physiol. Biochem.
Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis
Abdom. Radiol. (New York)
Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma
Cell. Physiol. Biochem.
Liver transplantation for alcoholic liver disease and hepatocellular carcinoma
Cancers (Basel)
Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma
BMC Cancer
Liver transplantation vs liver resection in patients with HBV-related hepatocellular carcinoma beyond Milan criterion: a meta-analysis
Clin. Transplant.
Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma
J. Hepatocell. Carcinoma
Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
J. Gastroenterol.
Clinicopathological and prognostic significance of OCT4 in patients with hepatocellular carcinoma: a meta-analysis
Onco Targets Ther.
HIF1alphainduced upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by inactivating the PTEN/AKT signaling pathway
Oncol. Rep.
Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer
Am. J. Transl. Res.
Silencing of urothelial carcinoma associated 1 inhibits the proliferation and migration of medulloblastoma cells
Med. Sci. Monit.
LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway
Oncol. Lett.
LncRNA UCA1 promotes mitochondrial function of bladder cancer via the MiR-195/ARL2 signaling pathway
Cell. Physiol. Biochem.
Cited by (18)
UCA1 long non-coding RNA: An update on its roles in malignant behavior of cancers
2019, Biomedicine and PharmacotherapyEmerging role of oncogenic long noncoding RNA as cancer biomarkers
2023, International Journal of CancerSerum LINC00152 and UCA1 in HCV-Induced Hepatocellular Carcinoma: Clinical Significance and Prognostic Value
2023, Biologics: Targets and TherapyHigh Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma
2022, Frontiers in Molecular Biosciences
- 1
Equal contributors.